AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19673939 — intervention group
Group type: COMPARATOR
Intervention: 20 mg/day atorvastatin
Number of subjects: 166
Study 17955648 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture plus TCM medication
Number of subjects: 61
Study 17955648 — intervention group
Group type: COMPARATOR
Intervention: TCM medication alone
Number of subjects: 61
Study 16096518 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (0.01-0.06 mg/kg/day)
Number of subjects: 163
Study 16096518 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study 11948054 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 10
Study 11948054 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 10
Study 9793283 — intervention group
Group type: EXPERIMENTAL
Intervention: Cavity wall treatments with copalite varnish or silver suspension
Number of subjects: 1117
Study 9793283 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional alloy
Number of subjects: 1117
Study 9793283 — intervention group
Group type: EXPERIMENTAL
Intervention: High copper alloy
Number of subjects: 1117
Study 9793283 — intervention group
Group type: EXPERIMENTAL
Intervention: 90-degree cavosurface angle combined with cavity wall finish
Number of subjects: 1117
Study 9793283 — intervention group
Group type: EXPERIMENTAL
Intervention: Operator and type of restoration (MO/DO vs MOD)
Number of subjects: 1117
Study 9793283 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment modalities
Number of subjects: 1117
Study 7814851 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin (10 mg/kg twice a day) for 4 days
Number of subjects: 0
Study 7814851 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin (10 mg/kg twice a day) and Indomethacin (50 mg twice a day) for 4 days
Number of subjects: 0
Study 7814851 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin alone
Number of subjects: 0
Study 7814851 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin
Number of subjects: 0
Study 2799763 — intervention group
Group type: EXPERIMENTAL
Intervention: PAI-1
Number of subjects: 0
Study 2799763 — intervention group
Group type: EXPERIMENTAL
Intervention: PAI-2
Number of subjects: 0
Study 2799763 — intervention group
Group type: EXPERIMENTAL
Intervention: Protease-nexin I
Number of subjects: 0
Study 31913254 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-Ingredient Preworkout Supplement (MIPS)
Number of subjects: 17
Study 31913254 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 17
Study 31172734 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai chi group (56 patients, mean age 71.61±7.97 years) practiced a 6-month Tai chi program, two times a week, plus standard care
Number of subjects: 98
Study 31172734 — intervention group
Group type: COMPARATOR
Intervention: Control group (42 patients, mean age 69.71±8.61 years) practiced usual care
Number of subjects: 98
Study 31172734 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai chi group
Number of subjects: 98
Study 28585746 — intervention group
Group type: EXPERIMENTAL
Intervention: AS cognitive concerns intervention
Number of subjects: 63
Study 28585746 — intervention group
Group type: COMPARATOR
Intervention: Repeated contact control
Number of subjects: 63
Study 26239831 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein breakfast (HP) - 35 g protein, 1,464 kJ
Number of subjects: 57
Study 26239831 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal-protein breakfast (NP) - 13 g protein, 1,464 kJ
Number of subjects: 57
Study 26239831 — intervention group
Group type: COMPARATOR
Intervention: Control (CON) - skipped breakfast
Number of subjects: 57
Study 23744697 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromelanin MRI
Number of subjects: 70
Study 23744697 — intervention group
Group type: EXPERIMENTAL
Intervention: (123)I-metaiodobenzylguanidine scintigraphy
Number of subjects: 70
Study 23744697 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromelanin MRI and (123)I-metaiodobenzylguanidine scintigraphy
Number of subjects: 70
Study 21439726 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored education and coaching (TEC)
Number of subjects: 265
Study 21439726 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (EUC)
Number of subjects: 265
Study 19406576 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored Barriers Intervention (TBI)
Number of subjects: 1256
Study 19406576 — intervention group
Group type: COMPARATOR
Intervention: Assessment‐alone
Number of subjects: 1256
Study 19406576 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 1256
Study 15290660 — intervention group
Group type: EXPERIMENTAL
Intervention: Alosetron 1 mg twice daily
Number of subjects: 246
Study 15290660 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 246
Study 10090436 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaprozin 1200 mg QD
Number of subjects: 679
Study 10090436 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabumetone 1500 mg QD
Number of subjects: 679
Study 10090436 — intervention group
Group type: COMPARATOR
Intervention: Nabumetone 1000 mg QD
Number of subjects: 679
Study 7586110 — intervention group
Group type: EXPERIMENTAL
Intervention: 26G Atraucan needle
Number of subjects: 96
Study 7586110 — intervention group
Group type: COMPARATOR
Intervention: 25G Whitacre needle
Number of subjects: 96
Study 2073296 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 300 mg daily
Number of subjects: 49
Study 2073296 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 1,200 mg daily
Number of subjects: 49
Study 2073296 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 7377748 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of sulfadiazine (SD) 250 mg + trimethoprim (TMP) 160 mg, given twice daily for one week.
Number of subjects: 85
Study 7377748 — intervention group
Group type: COMPARATOR
Intervention: Combination of sulfamethoxazole (SM) 800 mg + trimethoprim (TMP) 160 mg, given twice daily for one week.
Number of subjects: 85
Study 30994846 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality application
Number of subjects: 172
Study 30994846 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 172
Study 28408001 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin Awareness Intervention
Number of subjects: 0
Study 28408001 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 0
Study 25690840 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic swallowing exercises
Number of subjects: 44
Study 25690840 — intervention group
Group type: COMPARATOR
Intervention: Standard care (Control)
Number of subjects: 44
Study 23623452 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective sleep difficulty
Number of subjects: 693
Study 23623452 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 693
Study 23623452 — intervention group
Group type: EXPERIMENTAL
Intervention: Difficulty maintaining sleep
Number of subjects: 693
Study 23623452 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent nightmares
Number of subjects: 693
Study 23623452 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysomnographic %REM-sleep
Number of subjects: 693
Study 21542988 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) at an initial dose of 10 ppm
Number of subjects: 200
Study 21542988 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) at a subsequent dose of 20 ppm
Number of subjects: 200
Study 21542988 — intervention group
Group type: COMPARATOR
Intervention: Control group (no iNO)
Number of subjects: 200
Study 21542988 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) treated group
Number of subjects: 200
Study 19758357 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide (5 microg b.i.d. for 4 weeks then 10 microg b.i.d.)
Number of subjects: 1039
Study 19758357 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride (1 mg/day titrated to maximum dose)
Number of subjects: 1039
Study 18176139 — intervention group
Group type: EXPERIMENTAL
Intervention: Western medicine therapy (WM) including diclofenac extended action tablets, methotrexate, and sulfasalazine
Number of subjects: 396
Study 18176139 — intervention group
Group type: COMPARATOR
Intervention: Traditional Chinese medicine therapy (TCM) including Glucosidorum Tripterygll Totorum tablets and Yishen Juanbi tablets
Number of subjects: 396
Study 18176139 — intervention group
Group type: EXPERIMENTAL
Intervention: Western medicine therapy (WM)
Number of subjects: 396
Study 18176139 — intervention group
Group type: COMPARATOR
Intervention: Traditional Chinese medicine therapy (TCM)
Number of subjects: 396
Study 15170148 — intervention group
Group type: EXPERIMENTAL
Intervention: Helical CT imaging
Number of subjects: 371
Study 15170148 — intervention group
Group type: EXPERIMENTAL
Intervention: CT from university hospitals
Number of subjects: 371
Study 15170148 — intervention group
Group type: EXPERIMENTAL
Intervention: Panel assessment of CT imaging
Number of subjects: 371
Study 15170148 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-chemotherapy assessment
Number of subjects: 371
Study 15170148 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendation for additional radiotherapy
Number of subjects: 371
Study 11817797 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin modified GIC (Fuji II LC)
Number of subjects: 0
Study 11817797 — intervention group
Group type: COMPARATOR
Intervention: Amalgam
Number of subjects: 0
Study 9548155 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human FSH administered before the onset of the menstrual period (experimental group)
Number of subjects: 40
Study 9548155 — intervention group
Group type: COMPARATOR
Intervention: Control group (FSH administered in the early follicular phase after the onset of menses)
Number of subjects: 40
Study 9548155 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 7988063 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0
Study 7988063 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAIDs
Number of subjects: 0
Study 30355813 — intervention group
Group type: EXPERIMENTAL
Intervention: Metal post group (MP)
Number of subjects: 22
Study 30355813 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber post group (FP)
Number of subjects: 22
Study 30355813 — intervention group
Group type: COMPARATOR
Intervention: No post group (NP)
Number of subjects: 22
Study 27926462 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatty acid supplementation
Number of subjects: 296
Study 25193002 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 59
Study 25193002 — intervention group
Group type: COMPARATOR
Intervention: Waitlist
Number of subjects: 59
Study 23736351 — intervention group
Group type: EXPERIMENTAL
Intervention: HARP
Number of subjects: 168
Study 23736351 — intervention group
Group type: COMPARATOR
Intervention: LDN
Number of subjects: 168
Study 19727002 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum 299v (10^10 colony forming units/d)
Number of subjects: 0
Study 19727002 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19727002 — intervention group
Group type: COMPARATOR
Intervention: Lactobacillus plantarum 299v and Placebo
Number of subjects: 0
Study 19210650 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium, 18 microg once daily
Number of subjects: 78
Study 19210650 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol (50 microg) plus Fluticasone (200 microg), twice daily
Number of subjects: 78
Study 19210650 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium
Number of subjects: 78
Study 19210650 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol plus Fluticasone
Number of subjects: 78
Study 17086357 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of Survivin-expressing circulating cancer cells
Number of subjects: 67
Study 17086357 — intervention group
Group type: COMPARATOR
Intervention: Healthy women (control group)
Number of subjects: 67
Study 17086357 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Survivin-expression
Number of subjects: 67
Study 17086357 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative Survivin-expression
Number of subjects: 67
Study 15605005 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine injection plus bipolar probe coagulation
Number of subjects: 114
Study 15605005 — intervention group
Group type: COMPARATOR
Intervention: Bipolar probe coagulation alone
Number of subjects: 114
Study 11734581 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption (4 glasses of red wine, beer, spirits)
Number of subjects: 11
Study 11734581 — intervention group
Group type: EXPERIMENTAL
Intervention: Beer and spirits
Number of subjects: 11
Study 11734581 — intervention group
Group type: COMPARATOR
Intervention: Carbonated mineral water (control)
Number of subjects: 11
Study 9227341 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-view radiography and corresponding histological examination
Number of subjects: 40
Study 9227341 — intervention group
Group type: COMPARATOR
Intervention: Single-view specimen radiography and arbitrary histological sectioning
Number of subjects: 40
Study 7963068 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbid anxiety disorders
Number of subjects: 116
Study 7963068 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbid substance abuse/dependence
Number of subjects: 116
Study 7963068 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity and duration of an index episode of major depression
Number of subjects: 116
Study 7963068 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbid Axis I lifetime diagnoses
Number of subjects: 116
Study 3115354 — intervention group
Group type: COMPARATOR
Intervention: 20 per cent Lipofundin S (LCT)
Number of subjects: 60
Study 3115354 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipofundin 10 per cent MCT/10 per cent LCT
Number of subjects: 60
Study 29509295 — intervention group
Group type: EXPERIMENTAL
Intervention: Belatacept more intense (MI)
Number of subjects: 0
Study 29509295 — intervention group
Group type: EXPERIMENTAL
Intervention: Belatacept less intense (LI)
Number of subjects: 0
Study 29509295 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 0
Study 29509295 — intervention group
Group type: COMPARATOR
Intervention: Belatacept vs Cyclosporine
Number of subjects: 0
Study 29509295 — intervention group
Group type: EXPERIMENTAL
Intervention: Belatacept-based immunosuppression
Number of subjects: 0
Study 27448663 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group (rewards, feedback, behaviour change techniques)
Number of subjects: 776
Study 27448663 — intervention group
Group type: COMPARATOR
Intervention: Control Group (waiting list control)
Number of subjects: 776
Study 27448663 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group
Number of subjects: 776
Study 24762631 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy administration of fecal microbiota transplant (FMT)
Number of subjects: 20
Study 24762631 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasogastric tube (NGT) administration of fecal microbiota transplant (FMT)
Number of subjects: 20
Study 24762631 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cure rate after retreatment
Number of subjects: 20
Study 24762631 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily number of bowel movements
Number of subjects: 20
Study 24762631 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported health score
Number of subjects: 20
Study 24621933 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (target dose: 10 mg/d)
Number of subjects: 1654
Study 24621933 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1654
Study 24621933 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined results from both trials (including earlier study)
Number of subjects: 1654
Study 24621933 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 1654
Study 20148263 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular administration of MMRV vaccine
Number of subjects: 328
Study 20148263 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous administration of MMRV vaccine
Number of subjects: 328
Study 18266664 — intervention group
Group type: EXPERIMENTAL
Intervention: Current use of antipsychotics
Number of subjects: 22944
Study 18266664 — intervention group
Group type: EXPERIMENTAL
Intervention: Current use of antipsychotics (first week after initiation)
Number of subjects: 22944
Study 18266664 — intervention group
Group type: EXPERIMENTAL
Intervention: Current use of atypical antipsychotics
Number of subjects: 22944
Study 18266664 — intervention group
Group type: EXPERIMENTAL
Intervention: Current use of conventional antipsychotics
Number of subjects: 22944
Study 15845719 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative anxiety measurement
Number of subjects: 1389
Study 15845719 — intervention group
Group type: COMPARATOR
Intervention: Established predictors of PONV (sex, age, smoking, history of PONV or motion sickness, surgery type, anesthetic technique)
Number of subjects: 1389
Study 12851867 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 431
Study 12851867 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine (DES)
Number of subjects: 431
Study 12851867 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 431
Study 12851867 — intervention group
Group type: COMPARATOR
Intervention: Education (EDU)
Number of subjects: 431
Study 10098341 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflammatory bowel disease (IBD) patients
Number of subjects: 0
Study 10098341 — intervention group
Group type: EXPERIMENTAL
Intervention: Coeliac disease (CD) patients
Number of subjects: 0
Study 10098341 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 0
Study 9082344 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 1000 ml 0.16 M NaCl at 16.7 ml/min for 1 hour (induced hypervolemia)
Number of subjects: 24
Study 9082344 — intervention group
Group type: COMPARATOR
Intervention: Standard conditions (before infusion)
Number of subjects: 24
Study 2049965 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous or oral ofloxacin
Number of subjects: 58
Study 2049965 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ofloxacin
Number of subjects: 58
Study 2049965 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 58
Study 6357257 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin 1 mg
Number of subjects: 31
Study 6357257 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin 4 to 8 mg twice daily
Number of subjects: 31
Study 6357257 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydralazine 50 to 100 mg twice daily
Number of subjects: 31
Study 6357257 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of low doses of prazosin and hydralazine
Number of subjects: 31
Study 6357257 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin and hydralazine
Number of subjects: 31
Study 31037409 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (200 mg)
Number of subjects: 0
Study 31037409 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31037409 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 0
Study 27755982 — intervention group
Group type: COMPARATOR
Intervention: Asenapine 5mg
Number of subjects: 164
Study 27755982 — intervention group
Group type: COMPARATOR
Intervention: Asenapine 10mg
Number of subjects: 164
Study 27755982 — intervention group
Group type: COMPARATOR
Intervention: Placebo 5mg
Number of subjects: 164
Study 26824082 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbena officinalis Linn decoction (rinsing mouth with the decoction)
Number of subjects: 260
Study 26824082 — intervention group
Group type: COMPARATOR
Intervention: Control group (brushing and flossing only)
Number of subjects: 260
Study 25394502 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized magnesium sulphate (MgSO4)
Number of subjects: 508
Study 25394502 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (nebulized salbutamol and ipratropium bromide with isotonic saline)
Number of subjects: 508
Study 22849607 — intervention group
Group type: EXPERIMENTAL
Intervention: After-school exercise (n = 15)
Number of subjects: 29
Study 19461006 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (2 soft-gel pills of 1 g each containing EPA and DHA)
Number of subjects: 33
Study 19461006 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 soft-gel pills, no active ingredients)
Number of subjects: 33
Study 17461749 — intervention group
Group type: EXPERIMENTAL
Intervention: Media literacy curriculum
Number of subjects: 723
Study 15657476 — intervention group
Group type: EXPERIMENTAL
Intervention: TCAI group (multinutrient supplement containing TCAIs)
Number of subjects: 7
Study 15657476 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 7
Study 15657476 — intervention group
Group type: EXPERIMENTAL
Intervention: TCAI group
Number of subjects: 7
Study 11697813 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-chain fructo-oligosaccharides (sc-FOSs) 10 g/day
Number of subjects: 11
Study 11697813 — intervention group
Group type: COMPARATOR
Intervention: Sucrose (placebo)
Number of subjects: 11
Study 9390050 — intervention group
Group type: EXPERIMENTAL
Intervention: 568 ml (one pint) of whole or reduced fat milk per day for 18 months
Number of subjects: 82
Study 9390050 — intervention group
Group type: COMPARATOR
Intervention: Control group (baseline average milk intake 150 ml)
Number of subjects: 82
Study 8198917 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 20
Study 8198917 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 20
Study 8198917 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 20
Study 3239338 — intervention group
Group type: EXPERIMENTAL
Intervention: IUD without tail (study group)
Number of subjects: 1183
Study 3239338 — intervention group
Group type: COMPARATOR
Intervention: IUD with tail (control group)
Number of subjects: 1183
Study 3239338 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (pooled data)
Number of subjects: 1183